Parasitology Research

, Volume 95, Issue 6, pp 420–426 | Cite as

IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil

  • Cristiane G. Morais
  • Irene S. Soares
  • Luzia H. Carvalho
  • Cor Jesus F. Fontes
  • Antoniana U. Krettli
  • Érika Martins Braga
Original Paper


Subclasses of antibodies to the C-terminal 19 kDa fragment of the Plasmodium vivax merozoite surface protein 1 (PvMSP-119) were assessed among subjects with distinct degrees of malaria exposure in the Brazilian endemic area. The PvMSP-119 specific IgG1and IgG3 levels were low among subjects with long-term exposure (~19 years) when compared to subjects less and sporadically exposed (<1 year). No statistically difference was observed in IgG subclass distribution of antibodies from symptomatic Plasmodium-infected patients, asymptomatic parasite carriers and non-infected subjects living in a same mesoendemic area. Subjects briefly exposed to a P. vivax outbreak living in a rural community outside the endemic area were also evaluated to measure the persistence of specific antibodies. IgG anti-PvMSP-119 antibodies persisted in 40% of the subjects who had had malarial symptoms 8 months before and decreased after 7 years (28%). Specific IgG1 were the predominant isotype. Our study emphasizes the highly immunogenicity of the PvMSP-119 and points toward its possible use as a potential malaria vaccine.


Malaria Malaria Transmission Vivax Malaria Malaria Vaccine Reactivity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was financially supported by Fundação de Amparo à Pesquisa do Estado de Minas Gerais FAPEMIG (grant no. CBB2323/97). Informed consent was obtained from subjects according to the Universidade Federal de Minas Gerais Ethics Committee (15 April 1998) and Fundação Oswaldo Cruz Ethics Committee (26 November 1994).


  1. Blackman MJ, Heidrich H, Donachie S, Mcbride JS, Holder AA (1990) A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172:379–382Google Scholar
  2. Blackman MJ, Ling IT, Nicholls SC, Holder AA (1991) Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol 49:29–33Google Scholar
  3. Braga EM, Fontes CJF, Krettli AU (1998) Persistence of humoral response against sporozoite and blood-stage malaria antigens 7 years after a brief exposure to Plasmodium vivax. J Infect Dis 177:1132–1135Google Scholar
  4. Braga EM, Barros RM, Reis TA, Fontes CJF, Morais CG, Martins MS, Krettli AU (2002) Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region. Am J Trop Med Hyg 66:461–466Google Scholar
  5. Branch OH, Oloo AJ, Nahlen BL, Kaslow D, Lal AA (2000) Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay cohort project. J Infect Dis 181:1746–1752Google Scholar
  6. Cunha MG, Rodrigues MM, Soares IS (2001) Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP119 expressed in distinct bacterial vectors. Vaccine 20:385–396Google Scholar
  7. Dekker C, Uthaipibull C, Calder LJ, Lock M, Grainger M, Morgan WD, Dodson GG, Holder AA (2004) Inhibitory and neutral antibodies to Plasmodium falciparum MSP119 form ring structures with their antigen. Mol Biochem Parasitol 137:143–149Google Scholar
  8. Dodoo D, Theander TG, Kurtzhals JA, Koram K, Riley E, Akanmori BD, Nkrumah FK, Hviid L (1999) Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun 67:2131–2137Google Scholar
  9. Egan AE, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder A, Riley EM (1996) Clinical immunity P. falciparum malaria is associated with serum antibodies to the 19 kDa C-terminal fragment of the merozoite surface antigen PfMSP1. J Infect Dis 173:765–769Google Scholar
  10. Engers HD, Godal T (1998) Malaria vaccine development: current status. Parasitol Today 14:56–64Google Scholar
  11. Fontes CJF (2001) Malária assintomática em áreas de garimpo no Brasil: estudos de fatores de risco. Belo Horizonte: Faculdade de Medicina da Universidade Federal de Minas Gerais. Belo Horizonte, PhD Thesis, p 178Google Scholar
  12. Fontes CJF, Bathurst I, Krettli AU (1991) Plasmodium vivax sporozoite antibodies in individuals exposed during a single malaria outbreak in a non-endemic area. Am J Trop Med Hyg 44:28–33Google Scholar
  13. Fraser T, Michon P, Barnwell JW, Noe AR, Al-Yaman F, Kaslow DC, Adams JH (1997) Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect Immun 65:2772–2777Google Scholar
  14. Han HJ, Park SG, Kim SH, Hwang SY, Han J, Traicoff J, Kho WG, Chung JY (2004) Epidermal growth factor-like motifs 1 and 2 of Plasmodium vivax merozoite surface protein 1 are critical domains in erythrocyte invasion. Biochem Biophys Res Commun 320:563–570Google Scholar
  15. Holder AA (1988) The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy 41:72–97Google Scholar
  16. Holder AA, Guevara Patino JA, Uthaipibull C, Syed SE, Ling IT, Scott-Finnigan T, Blackman MJ (1999) Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 41:409–414Google Scholar
  17. Lim KJ, Park JW, Yeom JS, Lee YH, Yoo SB, Oh JH, Sohn MJ, Bahk YY, Kim YS (2004) Humoral responses against the C-terminal region of merozoite surface protein 1 can be remembered for more than 30 years in persons exposed to Plasmodium vivax. Parasitol Res 92:384–389Google Scholar
  18. Marques AC (1987) Human migration and the spread of malaria in Brazil. Parasitol Today 3:166–170Google Scholar
  19. O’Donnell RA, De Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, Crabb BS (2001) Antibodies against merozoite surface protein MSP-119 are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 193:1403–1412Google Scholar
  20. Parish CR (1972) The relationship between humoral and cell-mediated immunity. Transplant Rev 13:35–66Google Scholar
  21. Park JW, Moon SH, Yeom JS, Lim KJ, Sohn MJ, Jung WC, Cho YJ, Jeon KW, Ju W, Ki CS, Oh MD, Che KW (2001) Naturally acquired antibody responses to the C-terminal region of the merozoite surface protein 1 of Plasmodium vivax in Korea. Clin Diagn Lab Immunol 8:14–20Google Scholar
  22. Pasay MC, Cheng Q, Rzepczyk C, Saul A (1995) Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1. Mol Biochem Parasitol 70:217–219Google Scholar
  23. Riley EM, Wagner GE, Ofori MF, Wheeler JG, Akanmori BD, Tetteh K, McGuinness D, Bennett S, Nkrumah FK, Anders RF, Koram KA (2000) Lack of association between maternal antibody and protection of African infants from malaria infection. Infect Immun 68:5856–5863Google Scholar
  24. Sawyer D (1993) Economic and social consequences of malaria in new colonization projects in Brazil. Soc Sci Med 37:1131–1136Google Scholar
  25. Scopel KKG, Fontes CJF, Nunes AC, Horta MF, Braga EM (2004) Low sensitivity of nested PCR using Plasmodium DNA extracted from stained thick blood smears: an epidemiological retrospective study among subjects with low parasitemias in a Brazilian Amazon endemic area. Malar J 3:8Google Scholar
  26. Soares IS, Levitus G, Souza JM, Del Portillo HA, Rodrigues MM (1997) Acquired immune responses to the N- and C-terminal regions of P. vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun 65:1606–1614Google Scholar
  27. Soares IS, Oliveira SG, Souza JM, Rodrigues MM (1999a) Antibody response to the N- and C-terminal regions of the Merozoite surface protein 1 in individuals living in an area of exclusive transmission of Plasmodium vivax malaria in the north of Brazil. Acta Trop 72:13–24Google Scholar
  28. Soares IS, Cunha MG, Silva MN, Souza JM, Del Portillo HA, Rodrigues MM (1999b) Longevity of the naturally acquired antibody responses to the N- and C-terminal regions of P. vivax MSP1. Am J Trop Med Hyg 60:357–363Google Scholar
  29. Soares IS, Barnwell JW, Ferreira MU, Cunha MG, Laurino JP, Castilho BA, Rodrigues MM (1999c) A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies. Mol Med 5:459–470Google Scholar
  30. Taylor-Robinson AW (1998) Immunoregulation of malarial infection: balancing the vices and virtues. Int J Parasitol 28:135–148Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Cristiane G. Morais
    • 1
  • Irene S. Soares
    • 2
  • Luzia H. Carvalho
    • 3
  • Cor Jesus F. Fontes
    • 4
  • Antoniana U. Krettli
    • 1
    • 3
  • Érika Martins Braga
    • 1
  1. 1.Departamento de Parasitologia, Instituto de Ciências BiológicasUniversidade Federal de Minas GeraisBelo HorizonteBrazil
  2. 2.Departamento de Análises Clínicas e ToxicológicasUniversidade de São PauloSao PauloBrazil
  3. 3.Centro de Pesquisas René Rachou/FIOCRUZBelo HorizonteBrazil
  4. 4.Departamento de Clínica MédicaUniversidade Federal de Mato GrossoCuiabaBrazil

Personalised recommendations